To Develop ADC Anti-cancer Drugs
Chong Kun Dang announced on Feb. 3 that it has licensed antibody-drug conjugate (ADC) technology from Synaffix B.V., a Dutch biotechnology company.
The contract amount is approximately US$132 million including the down payment and development, licensing and sales milestones.
With this contract, Chong Kun Dang has secured the right to use Synaffix’s three ADC technology platforms, GlycoConnect, HydraSpace, and toxSYN, and plans to develop ADC anti-cancer drugs.
Synaffix’s ADC technology platforms are a next-generation technology that can realize site-specific conjugation by conjugating an exact number of drugs to an antibody at a precise location.
“Chong Kun Dang is building expertise and know-how through the development of various anti-cancer drugs, including small cell lung cancer drug Calmtobell and anti-cancer bispecific antibody CKD-702,” said Kim Young-joo, CEO of Chong Kun Dang. “We will speed up the development of anticancer drugs through this deal with Synaffix.”
In the meantime, Chong Kun Dang is expediting the development of next-generation anticancer drugs based on ADC technology by establishing an ADC target discovery model using its own bioinformatics database and selecting a number of additional targets to build an ADC pipeline portfolio.